ICER publishes evidence report on treatment for schizophrenia

25 January 2024 - KarXT has a novel mechanism of action, but there are significant uncertainties regarding long term efficacy ...

Read more →

Highlights from the 22-25 January 2024 CHMP meeting

26 January 2024 - The EMA’s CHMP recommended three medicines for approval at its January 2024 meeting. ...

Read more →

Outcomes from the December 2023 PBAC intracycle meeting

25 January 2024 - The outcomes from the December 2023 PBAC intracycle meeting are now available. ...

Read more →

PHARMAC joins global health technology assessment network

25 January 2024 - PHARMAC has joined the International Network of Agencies for Health Technology Assessment (INAHTA) - a network ...

Read more →

Remdesivir and the combination of tixagevimab and cilgavimab for the treatment of patients with COVID-19 disease

18 January 2024 - NICE has published additional draft guidance on the use of remdesivir and the combination of tixagevimab ...

Read more →

PHARMAC publishes agenda for next month's PTAC meeting

18 January 2024 - Surprise, surprise yet another underwhelming agenda. ...

Read more →

NICE issues draft guidance for use of remdesivir and also for tixagevimab-cilgavimab for treatment of COVID-19

18 January 2024 - Draft guidance for public consultation has been published by NICE. ...

Read more →

EMA publishes agenda for 22-25 January 2024 CHMP meeting

22 January 2024 - The EMA has published a draft agenda for this week's CHMP meeting. ...

Read more →

300 people to benefit from new treatment for advanced breast cancer recommended by NICE following price deal

19 January 2024 - Around 300 people are set to benefit following NICE’s recommendation of talazoparib tosylate for treating a type ...

Read more →

New orphan drug for a sub-type of acute myeloid leukaemia: G-BA sees significant additional benefit

18 January 2024 - Since July 2023, there has been one in Germany for patients who suffer from acute myeloid leukaemia ...

Read more →

Updates to the HTA Policy and Methods Review Reference Committee (18 January 2024)

18 January 2024 - Communiques for three HTA Review Reference Committee meetings held in December 2023 are now available. ...

Read more →

Olaparib in combination with bevacizumab for the maintenance treatment of adults with advanced high grade epithelial ovarian, fallopian tube or primary peritoneal cancer

17 January 2024 - NICE has published evidence-based recommendations on the use of olaparib (Lynparza) in combination with bevacizumab (Avastin) ...

Read more →

SMC - January 2024 decisions

15 January 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...

Read more →

Sebelipase alfa for the treatment of patients with Wolman disease (final guidance)

10 January 2023 - Sebelipase alfa is recommended as an option for the treatment of patients with Wolman disease only if ...

Read more →

DoH publishes revised agenda for March 2024 PBAC meeting (version 3)

5 January 2024 - The Department of Health has published a revised agenda (version 3) for the March 2024 PBAC ...

Read more →